NASDAQ:BGNEBeigene Stock Price, Forecast & News

Beigene's stock was trading at $145.69 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, BGNE stock has increased by 51.3% and is now trading at $220.50.
View which stocks have been most impacted by Coronavirus.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Beigene in the last year. There are currently 5 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Beigene.

Beigene is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Beigene.

Beigene Ltd (NASDAQ:BGNE) posted its earnings results on Thursday, August, 6th. The company reported ($4.31) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($4.78) by $0.47. Beigene had a negative return on equity of 82.03% and a negative net margin of 620.47%.
View Beigene's earnings history.

13 equities research analysts have issued 12 month price targets for Beigene's shares. Their forecasts range from $165.00 to $268.00. On average, they anticipate Beigene's share price to reach $215.75 in the next twelve months. This suggests that the stock has a possible downside of 2.2%.
View analysts' price targets for Beigene.

News articles about BGNE stock have trended very positive this week, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Beigene earned a media sentiment score of 4.0 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term.
View the latest news about Beigene.

Some companies that are related to Beigene include Celgene (CELG), Zoetis (ZTS), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Bayer (BAYRY), Takeda Pharmaceutical (TAK), ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Royalty Pharma (RPRX), UCB (UCBJF), Genmab A/S (GMAB), Alexion Pharmaceuticals (ALXN), Genmab A/S (GNMSF), Shiseido (SSDOY) and BioMarin Pharmaceutical (BMRN).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Beigene investors own include NVIDIA (NVDA), Alibaba Group (BABA), Crispr Therapeutics (CRSP), Square (SQ), Editas Medicine (EDIT), Intellia Therapeutics (NTLA), Intuitive Surgical (ISRG), InVitae (NVTA), AbbVie (ABBV) and JD.Com (JD).

(BGNE) raised $126 million in an initial public offering (IPO) on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company acted as the underwriters for the IPO and Baird was co-manager.

Beigene trades on the NASDAQ under the ticker symbol "BGNE."

Beigene's stock is owned by many different retail and institutional investors. Top institutional shareholders include Matthews International Capital Management LLC (0.32%), Sumitomo Mitsui Trust Holdings Inc. (0.22%), Candriam Luxembourg S.C.A. (0.21%), Swiss National Bank (0.17%), New York State Common Retirement Fund (0.10%) and Edmond DE Rothschild Holding S.A. (0.08%). Company insiders that own Beigene stock include Amy C Peterson, Donald W Glazer, Howard Liang, Jane Huang, John Oyler, Timothy Yung-Cheng Chen, Xiaobin Wu and Xiaodong Wang.
View institutional ownership trends for Beigene.

BGNE stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Matthews International Capital Management LLC, DekaBank Deutsche Girozentrale, Sumitomo Mitsui Trust Holdings Inc., Vident Investment Advisory LLC, Vident Investment Advisory LLC, Mckinley Capital Management LLC Delaware, and Profund Advisors LLC. Company insiders that have sold Beigene company stock in the last year include Donald W Glazer, Howard Liang, Jane Huang, John Oyler, Timothy Yung-Cheng Chen, Xiaobin Wu, and Xiaodong Wang.
View insider buying and selling activity for Beigene.

BGNE stock was purchased by a variety of institutional investors in the last quarter, including MERIAN GLOBAL INVESTORS UK Ltd, Candriam Luxembourg S.C.A., M&G Investment Management Ltd., Edmond DE Rothschild Holding S.A., New York State Common Retirement Fund, Swiss National Bank, Banco de Sabadell S.A, and Jennison Associates LLC.
View insider buying and selling activity for Beigene.

Shares of BGNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of BGNE stock can currently be purchased for approximately $220.50.

Beigene has a market capitalization of $19.70 billion and generates $428.21 million in revenue each year. The company earns $-948,630,000.00 in net income (profit) each year or ($15.80) on an earnings per share basis. Beigene employs 3,500 workers across the globe.

The official website for Beigene is www.beigene.com.

Beigene's mailing address is 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN E9, KY1-1108. The company can be reached via phone at 1-345-949-4123 or via email at [email protected]